---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-256110"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2022-10-03T23:59:59+00:00"
generated_at: "2026-06-23T05:56:38.187319+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aura reports Phase 2 interim data: 89% tumor control, significant growth rate reduction for choroidal melanoma

## Summary
- Interim Phase 2 data for belzupacap sarotalocan (AU-011) in early-stage choroidal melanoma show 88.9% (8/9) tumor control rate at therapeutic regimen.
- Statistically significant reduction in tumor growth rate of -0.296 mm/year (p=0.0007) vs. documented historical growth.
- Visual acuity preservation rate of 88.9% (8/9) in highest dose cohorts; most tumors were near fovea or optic disc.
- No dose-limiting toxicities or treatment-related serious adverse events reported; mild anterior inflammation in 20%.
- Data support planned pivotal program; company held virtual investor day on October 3, 2022.

## SEC filing metadata
- accession: 0001193125-22-256110
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2022-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312522256110/0001193125-22-256110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312522256110/d251752d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-256110
- JSON: https://secwatch.observer/filing/0001193125-22-256110.json
- Plain text: https://secwatch.observer/filing/0001193125-22-256110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.